Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$34.63 USD
-1.96 (-5.36%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $34.61 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
DYN 34.63 -1.96(-5.36%)
Will DYN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DYN
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Other News for DYN
Dyne Therapeutics to Present at Chardan?s 8th Annual Genetic Medicines Conference
Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc
Deep Track Capital, LP Increases Stake in Dynavax Technologies Corp
Dyne Therapeutics participates in a conference call with JPMorgan
Dyne Therapeutics participates in a conference call with JPMorgan